136 related articles for article (PubMed ID: 17382019)
1. Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors.
Atallah E; Kantarjian H; Cortes J
Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 3():S105-12. PubMed ID: 17382019
[TBL] [Abstract][Full Text] [Related]
2. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
Beyer C; Distler JH; Distler O
Swiss Med Wkly; 2010; 140():w13050. PubMed ID: 20419513
[TBL] [Abstract][Full Text] [Related]
3. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib.
Amitay-Laish I; Stemmer SM; Lacouture ME
Dermatol Ther; 2011; 24(4):386-95. PubMed ID: 21910796
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
5. [Inhibitors for ABL, KIT and PDGFR tyrosine kinases--imatinib, nitotinib, and dasatinib].
Nishida T; Tsukazaki K
Nihon Rinsho; 2015 Feb; 73 Suppl 2():250-5. PubMed ID: 25831762
[No Abstract] [Full Text] [Related]
6. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
O'Hare T; Eide CA; Deininger MW
Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
[TBL] [Abstract][Full Text] [Related]
7. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Hochhaus A
Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate.
Waller CF
Recent Results Cancer Res; 2010; 184():3-20. PubMed ID: 20072827
[TBL] [Abstract][Full Text] [Related]
10. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
11. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
[TBL] [Abstract][Full Text] [Related]
12. [Imatinib and solid tumours].
Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
Li J; Xu G; Yu S; He L; Guo L
J Int Med Res; 2011; 39(2):337-47. PubMed ID: 21672337
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
15. Secondary malignancy after imatinib therapy: eight cases and review of the literature.
Duman BB; Paydas S; Disel U; Besen A; Gurkan E
Leuk Lymphoma; 2012 Sep; 53(9):1706-8. PubMed ID: 22329351
[TBL] [Abstract][Full Text] [Related]
16. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.
Distler JH; Distler O
Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v10-1. PubMed ID: 18784126
[TBL] [Abstract][Full Text] [Related]
17. Defining and managing imatinib resistance.
Mauro MJ
Hematology Am Soc Hematol Educ Program; 2006; ():219-25. PubMed ID: 17124064
[TBL] [Abstract][Full Text] [Related]
18. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
Dagher R; Cohen M; Williams G; Rothmann M; Gobburu J; Robbie G; Rahman A; Chen G; Staten A; Griebel D; Pazdur R
Clin Cancer Res; 2002 Oct; 8(10):3034-8. PubMed ID: 12374669
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib: is it all in the dose?
Condorelli F; Genazzani AA
BioDrugs; 2010 Jun; 24(3):157-63. PubMed ID: 20222756
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate in the treatment of hematologic malignancies.
Piccaluga PP; Rondoni M; Paolini S; Rosti G; Martinelli G; Baccarani M
Expert Opin Biol Ther; 2007 Oct; 7(10):1597-611. PubMed ID: 17916051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]